文献速递心律失常冠心病

导管消融与索他洛尔或胺碘酮治疗室性心动过速:VANISH2 试验亚组分析

Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-10-11

VANISH2 预设亚组分析按药物 eligibility 分层比较导管消融与抗心律失常药物。索他洛尔合格层消融组主要复合终点风险更低(HR 0.64,95%CI 0.43-0.94,P=0.02);胺碘酮合格层两组疗效相当,但胺碘酮组不良事件更突出。

要点

  • 索他洛尔合格层:消融较索他洛尔降低主要复合终点风险(HR 0.64,P=0.02)。
  • 胺碘酮合格层:消融与胺碘酮疗效相当(HR 0.86,P=NS)。
  • 胺碘酮合格层:药物组非心脏死亡、呼吸衰竭、心衰住院等不良事件更多。

核心结论

  • 在索他洛尔合格患者中,导管消融较索他洛尔降低主要复合终点风险。
  • 在胺碘酮合格患者中,导管消融与胺碘酮的疗效终点相当。
  • 胺碘酮组不良事件更突出,包括非心脏死亡、呼吸衰竭、心衰住院、脓毒症、肺炎和肺纤维化/浸润。

研究设计与样本

  • VANISH2 多中心随机试验的预设亚组分析,纳入既往心肌梗死伴室性心动过速患者。
  • 按药物合格性分层随机:索他洛尔合格层(eGFR≥30 mL/min、NYHA I-II、LVEF≥20%、非电风暴、无尖端扭转型室速或QT延长史)随机至消融或索他洛尔;其余随机至消融或胺碘酮。
  • 共 416 例患者(索他洛尔层 199 例,胺碘酮层 217 例),中位随访 4.3 年。
  • 主要终点为死亡、适当 ICD 放电、VT 电风暴或随机化后 >14 天治疗的持续性 VT(低于 ICD 检测限)的复合终点。

主要发现

  • 索他洛尔层:消融组 95 例中 44 例(46%)发生主要终点,索他洛尔组 104 例中 62 例(59%)发生(HR 0.64;95%CI 0.43-0.94;P=0.02)。
  • 胺碘酮层:消融组 108 例中 59 例(55%)发生主要终点,药物组 109 例中 67 例(61%)发生(HR 0.86;95%CI 0.61-1.22;P=NS)。
  • 索他洛尔层:低于检测限的持续性 VT 在消融组 95 例中 2 例(2.1%),索他洛尔组 104 例中 18 例(17.3%)(HR 0.12;95%CI 0.03-0.5;P=0.004)。
  • 胺碘酮层:低于检测限的持续性 VT 在消融组 108 例中 7 例(6.5%),胺碘酮组 109 例中 17 例(15.6%)(HR 0.41;95%CI 0.17-0.99;P=0.048)。
  • 胺碘酮层:药物组较消融组非心脏死亡增加 3 倍(5.6% vs 16.5%)、呼吸衰竭增加 2 倍(4.6% vs 11.0%)、心衰住院增加 50%(19.4% vs 31.2%)、脓毒症增加 65%(5.6% vs 9.2%)、肺炎增加 3 倍(3.7% vs 11.9%),肺纤维化/浸润发生率为 4.6%(消融组 0%)。

临床怎么用

  • 对既往心肌梗死伴 VT 且符合索他洛尔条件的患者,导管消融可作为优于索他洛尔的选择。
  • 对符合胺碘酮条件的患者,消融与胺碘酮疗效相当,但需权衡胺碘酮相关不良事件风险。

局限性

  • 本文为预设亚组分析,各层样本量有限。
  • 原文未报告亚组分析的多重比较校正方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the VANISH2 multicenter randomized trial comparing catheter ablation to antiarrhythmic drugs (AADs) for patients with prior myocardial infarction and ventricular tachycardia (VT), randomization was stratified by drug eligibility based on clinical criteria. OBJECTIVES: The objective of this prespecified substudy was to compare the outcomes of catheter ablation vs AAD according to drug eligibility stratum. METHODS: Patients were considered eligible to be allocated to sotalol vs ablation if they met all the following criteria: estimated glomerular filtration rate ≥30 mL/min, NYHA functional class I-II, left ventricular ejection fraction ≥20%, qualifying arrhythmia was not VT storm, and no history of torsades de pointes or QT interval prolongation. All other patients were eligible to be randomly allocated to amiodarone vs ablation. The primary endpoint was a composite of death, appropriate implantable cardioverter-defibrillator shock, VT storm, or treated sustained VT below the detection limit of the implantable cardioverter-defibrillator >14-days postrandomization. Secondary endpoints included safety and the individual components of the primary endpoint. In this analysis, the primary and secondary outcomes for catheter ablation are compared with those for sotalol and to amiodarone separately. RESULTS: A total of 416 patients (199 in sotalol and 217 in amiodarone strata) were followed for a median of 4.3 years. In the sotalol stratum, a primary endpoint occurred in 44 of 95 patients (46%) assigned to catheter ablation and in 62 of 104 (59%) assigned to sotalol (HR: 0.64; 95% CI: 0.43-0.94; P = 0.02). In the amiodarone stratum, a primary endpoint occurred in 59 of 108 (55%) patients assigned to ablation and 67 of 109 (61%) assigned to AAD (HR: 0.86; 95% CI: 0.61-1.22; P = NS). In the sotalol stratum, sustained VT below detection occurred in 2 of 95 (2.1%) patients randomized to ablation and 18 of 104 (17.3%) assigned to sotalol (HR: 0.12; 95% CI: 0.03-0.5; P = 0.004). In the amiodarone stratum it occurred in 7 of 108 (6.5%) randomized to ablation and 17 of 109 (15.6%) assigned to amiodarone (HR: 0.41; 95% CI: 0.17-0.99; P = 0.048). In the amiodarone stratum, patients allocated to drug therapy had a 3-fold increase in noncardiac death (5.6% vs 16.5%), a 2-fold increase in respiratory failure (4.6% vs 11.0%), a 50% increase in heart failure hospitalization (19.4% vs 31.2%), a 65% increase in sepsis (5.6% vs 9.2%), a 3-fold increase in pneumonia (3.7% vs 11.9%), and 4.6% incidence of pulmonary fibrosis/infiltrate (vs 0%), when compared with patients allocated to ablation. CONCLUSIONS: In the sotalol-eligible patients, ablation led to lower risk of the primary composite endpoint. In the amiodarone-eligible group, efficacy outcomes were comparable between ablation and amiodarone. Adverse events were more marked among patients randomized to amiodarone (Antiarrhythmics or Ablation for Ventricular Tachycardia 2 [VANISH2]; NCT02830360).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nery PB, Wells GA, Tang ASL, et al. Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial. J Am Coll Cardiol. 2025. PMID: 41217320. doi:10.1016/j.jacc.2025.09.1595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。